Profound Medical Corp
TSX:PRN

Watchlist Manager
Profound Medical Corp Logo
Profound Medical Corp
TSX:PRN
Watchlist
Price: 10.03 CAD 0.3%
Market Cap: 247.4m CAD
Have any thoughts about
Profound Medical Corp?
Write Note

Profound Medical Corp
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Profound Medical Corp
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Profound Medical Corp
TSX:PRN
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Short-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Short-Term Debt
CA$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theralase Technologies Inc
XTSX:TLT
Short-Term Debt
CA$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedMira Inc
XTSX:MIR
Short-Term Debt
CA$6m
CAGR 3-Years
740%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
Ondine Biomedical Inc
LSE:OBI
Short-Term Debt
CA$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Profound Medical Corp
Glance View

Market Cap
247.4m CAD
Industry
Health Care

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

PRN Intrinsic Value
5.75 CAD
Overvaluation 43%
Intrinsic Value
Price

See Also

What is Profound Medical Corp's Short-Term Debt?
Short-Term Debt
0 USD

Based on the financial report for Sep 30, 2024, Profound Medical Corp's Short-Term Debt amounts to 0 USD.

Back to Top